Suturable DuraGen™ PMCF Study

NCT ID: NCT04923867

Last Updated: 2025-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

106 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-04-28

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary goal of this study is to retrospectively collect data on the safety and efficacy of Suturable DuraGen™.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter, non-randomized, non-interventional, retrospective Post-Market Clinical Follow-up (PMCF) study to evaluate the occurrence of post-operative cerebrospinal fluid (CSF) leaks within 30 days (and up to 90 days) after use of Suturable DuraGen™ for a supratentorial, infratentorial, or spinal procedure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebrospinal Fluid Leak

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supratentorial Procedure Group

Subjects that have undergone a supratentorial procedure with the use of Suturable DuraGen™.

Suturable DuraGen™

Intervention Type DEVICE

Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.

Infratentorial Procedure Group

Subjects that have undergone a infratentorial procedure with the use of Suturable DuraGen™.

Suturable DuraGen™

Intervention Type DEVICE

Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.

Spinal Procedure Group

Subjects that have undergone a spinal procedure with the use of Suturable DuraGen™.

Suturable DuraGen™

Intervention Type DEVICE

Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Suturable DuraGen™

Suturable DuraGen™ Dural Regeneration Matrix, an absorbable implant for repair of dural defects.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is between 18 and 80 years of age
2. Subject has undergone either a supratentorial, an infratentorial, or a spinal procedure with the use of Suturable DuraGen™ prior to trial initiation
3. Availability of post-operative assessment results.

Exclusion Criteria

1\. There are no exclusionary criteria for this study population
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Integra LifeSciences Corporation

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrew Tummon

Role: STUDY_DIRECTOR

Integra LifeSciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Site Status

Baptist Medical Center

Jacksonville, Florida, United States

Site Status

Oregon Health & Science University

Portland, Oregon, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C-DGSUT-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Medtronic PSR TDD PMCF
NCT04714385 COMPLETED
Study With Fascigel
NCT05625984 COMPLETED NA